Related Experiment Video
Updated: Jun 17, 2025
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
Computational insights into CRISP3 downregulation in cervical cancer and its cervical lineages pattern
Ricardo Cesar Cintra1, Andrés Galindo Céspedes2, Mércia Patrícia Ferreira Conceição1
1Department of Oncology, Universidade de São Paulo, São Paulo 71.961-540, Brazil.
Background:
Cysteine-rich secretory protein 3 (CRISP3) emerges as a potential biomarker in the study of many cancers, including cervical cancer (CC). This study aimed to analyze the expression pattern of CRISP3 in CC patients and CC cell lineages, following treatment with the epigenetic drugs: trichostatin A (TSA) and 5-aza-2'-deoxycytidine (5-aza).
Methods:
The differentially expressed genes identified in GSE63514 were used to construct a protein-protein interaction network. CRISP3 was selected for subsequent analyses. We utilized data from the TCGA and GENT2 projects to evaluate the expression profile and clinical behavior of CRISP3. Additionally, we conducted cell culture experiments to analyze the expression profile of CRISP3 in cells.
Results:
Low levels of CRISP3 were observed in squamous cell carcinoma (SCC) and human papillomavirus (HPV)16+, along with being associated with worse overall survival (OS). MIR-1229-3p was analyzed, and its high expression was associated with worse prognostic outcomes. In CC-derived cell lines, we observed low levels of CRISP3 in SiHa, followed by SW756, C33A, HeLa, and higher levels in CaSki. All cells were treated with TSA, 5-aza, or both. In all cell lines, treatment with TSA resulted in increased transcription of CRISP3.
Conclusion:
We identified a significant downregulation of CRISP3 in CC, particularly in cases with HPV16 infection and SCC, which was associated with poorer OS. Preliminary findings suggest that epigenetic treatments with TSA and 5-aza may modulate CRISP3 expression, warranting further research to elucidate its regulatory mechanisms and potential as a prognostic biomarker.
Insights
Cervical cancer (CC) shows low cysteine-rich secretory protein 3 (CRISP3) expression, linked to poorer survival. Epigenetic drugs like trichostatin A (TSA) may increase CRISP3 levels, suggesting potential as a biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Cervical cancer (CC) is a significant global health concern.
- Cysteine-rich secretory protein 3 (CRISP3) is implicated as a potential biomarker in various cancers.
- Understanding CRISP3 expression patterns in CC is crucial for developing novel diagnostic and therapeutic strategies.
Purpose of the Study:
- To investigate the expression profile of CRISP3 in cervical cancer (CC) patients and cell lines.
- To analyze the association between CRISP3 expression and clinical outcomes, including overall survival (OS).
- To evaluate the effect of epigenetic drugs, trichostatin A (TSA) and 5-aza-2'-deoxycytidine (5-aza), on CRISP3 expression in CC cells.
Main Methods:
- Utilized gene expression data from TCGA and GENT2 projects to assess CRISP3 expression and clinical behavior.
- Constructed a protein-protein interaction network using differentially expressed genes from GSE63514.
- Performed cell culture experiments on CC cell lines (SiHa, SW756, C33A, HeLa, CaSki) with and without TSA and 5-aza treatment.
Main Results:
- CRISP3 was significantly downregulated in CC, particularly in squamous cell carcinoma (SCC) and HPV16-positive cases, correlating with worse OS.
- High expression of MIR-1229-3p was associated with poorer prognostic outcomes.
- TSA treatment consistently increased CRISP3 transcription across all tested CC cell lines.
Conclusions:
- CRISP3 is downregulated in cervical cancer and serves as a potential prognostic biomarker, especially in SCC and HPV16-infected cases.
- Epigenetic modulation, specifically with TSA, can upregulate CRISP3 expression in CC cells.
- Further research is warranted to explore CRISP3's regulatory mechanisms and therapeutic potential in cervical cancer.
More Related Videos
09:16Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Related Concept Videos
02:02Cis-regulatory Sequences
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:23Abnormal Proliferation